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QDMRK was a phase III clinical trial of raltegravir given once daily (QD) (800-mg dose) versus twice daily (BID) (400 mg per
dose), each in combination with once-daily coformulated tenofovir-emtricitabine, in treatment-naive HIV-infected patients.
Pharmacokinetic (PK) and pharmacokinetic/pharmacodynamic (PK/PD) analyses were conducted using a 2-step approach: indi-
vidual non-model-based PK parameters from observed sparse concentration data were determined, followed by statistical analy-
sis of potential relationships between PK and efficacy response parameters after 48 weeks of treatment. Sparse PK sampling was
performed for all patients (QD, n  380; BID, n  384); selected sites performed an intensive PK evaluation at week 4 (QD, n 
22; BID, n  20). In the intensive PK subgroup, daily exposures (area under the concentration-time curve from 0 to 24 h
[AUC0 –24]) were similar between the two regimens, but patients on 800 mg QD experienced 4-fold-higher maximum drug con-
centration in plasma (Cmax) values and 6-fold-lower trough drug concentration (Ctrough) values than those on 400 mg BID.
Geometric mean (GM) Ctrough values were similarly lower in the sparse PK analysis. With BID dosing, there was no indication of
any significant PK/PD association over the range of tested PK parameters. With QD dosing, Ctrough values correlated with the
likelihood of virologic response. Failure to achieve an HIV RNA level of <50 copies/ml appeared predominantly at high baseline
HIV RNA levels in both treatment arms and was associated with lower values of GM Ctrough in the 800-mg-QD arm, though other
possible drivers of efficacy, such as time above a threshold concentration, could not be evaluated due to the sparse sampling
scheme. Together, these findings emphasize the importance of the shape of the plasma concentration-versus-time curve for long-
term efficacy.
The HIV-1 integrase inhibitor raltegravir, in combination withother antiretroviral agents, has demonstrated clinical efficacy
in treatment-experienced (4, 7, 8, 19, 20) and treatment-naive
(10–14,17) patients with HIV-1 infection. In a recent study (QD-
MRK), raltegravir given as an 800-mg dose once daily (QD) was
compared with the approved dosage of 400 mg twice daily (BID),
both in combination with tenofovir-emtricitabine, in treatment-
naive patients (6). Despite high response rates with both regimens,
raltegravir at 800 mg/day had inferior efficacy when given QD
rather than BID: after 48 weeks of treatment, 83% of patients
receiving QD raltegravir and 89% of patients receiving BID ralte-
gravir achieved viral RNA (vRNA) levels of 50 copies/ml.
Raltegravir pharmacokinetics (PK) exhibit considerable intra-
and intersubject variability (2, 9, 15, 22), which has complicated
the development of a population PK model to characterize the PK
in patients and contributes to difficulties in assessing the relevance
of PK data obtained at single or minimal time points (e.g., sparse
sampling). A population PK model based on data from six male
healthy volunteers was recently published (21), and a population
PK model based on data from both HIV-positive patients and
healthy subjects has been presented (1). However, it has not been
possible to develop an adequate model using a large data set rep-
resenting a mix of full profile and sparse sampling data from both
healthy subjects and HIV-infected patients collected in phase I, II,
and III studies under a variety of dosing conditions during the
raltegravir development program. The aforementioned intra- and
intersubject variability, together with the robust efficacy generally
observed for raltegravir-containing regimens, also limits the un-
derstanding of pharmacokinetic/pharmacodynamic (PK/PD) re-
lationships for raltegravir.
In the QDMRK study, sparse PK sampling was conducted with
all patients in addition to intensive PK sampling conducted with a
subset of approximately 20 patients per arm. This report describes
the individual PK parameters for raltegravir given once daily ver-
sus twice daily. We also investigated the relationship between
raltegravir PK parameters and virologic responses in HIV-in-
fected patients.
MATERIALS AND METHODS
QDMRK (MK-0518 protocol 071; NCT00745823) was a phase III nonin-
feriority study in treatment-naive HIV-1-infected adults that evaluated
the safety and efficacy of raltegravir given as an 800-mg dose once daily
versus the approved regimen of 400 mg twice daily, both given with once-
daily coformulated tenofovir at 300 mg plus emtricitabine at 200 mg.
Details regarding patient selection, treatment assignment, and virologic
assays have been previously described (6).
Pharmacokinetic and pharmacodynamic studies. Sparse PK sam-
pling was performed for all patients (n  380 [QD arm] or 384 [BID
arm]). One plasma sample was collected at weeks 2, 4, 8, 12, 16, 24, and 48;
these samples were collected predose at weeks 4, 8, 24, and 48 and irre-
spective of dosing time at other visits. At each visit, the study coordinator
recorded details of the patient’s food intake surrounding their last dose of
study therapy, specifically whether they had no food, a light meal, a mod-
erate meal, or a full meal within 2 h before or within 1 h after taking the
study drug. The exact time of the dose taken prior to collection of the
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sparse PK sample and the exact time the sparse PK sample was drawn were
also recorded. Selected sites performed an intensive PK evaluation at week
4 and therefore did not collect sparse PK samples at this visit (n  22 [QD
arm] or 20 [BID arm]). For the intensive PK evaluation, no specific in-
structions were given with regard to food intake around the time of dos-
ing. However, for the same visit during which the intensive PK samples
were drawn, patients were instructed to be in a fasted state for the collec-
tion of blood samples for safety labs. Thus, it is likely that the majority of
intensive PK was collected in the fasted state. Samples were collected at the
following time points: Predose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 h
postdose.
Determination of raltegravir concentrations in plasma. Plasma sam-
ples were analyzed for raltegravir concentrations at PharmaNet Canada,
Inc. (Quebec, Canada). The analytical method for the determination of
raltegravir in human plasma involves isolation, via 96-well liquid-liquid
extraction, of the analyte and internal standard from plasma, followed by
high-performance liquid chromatography-tandem mass spectrometry
(HPLC-MS/MS) analysis. The lower limit of quantitation (LLOQ) for the
plasma assay was 2 ng/ml (4.5 nM), and the linear calibration range was 2
to 1,000 ng/ml. More details regarding the bioanalysis can be found in the
previously published methods (16).
Pharmacokinetic analyses. For the subset of patients with intensive
PK profiles collected at week 4, a noncompartmental analysis was con-
ducted using the software program WinNonlin to calculate the area under
the concentration-time curve from 0 to 24 h (AUC0 –12), the concentra-
tion of drug in plasma at 12 h and maximum drug concentration (C12 and
Cmax), and the time to maximum concentration of drug in plasma (Tmax)
for patients in the BID treatment arm or AUC0 –24, C24, Cmax, and Tmax for
patients in the QD treatment arm. The linear up/log down method was
used for AUC calculation, and actual elapsed times postdose were used for
the analysis. Due to the large degree of interoccasion variability in the
absorption of raltegravir, a population PK model could not be developed,
and so traditional PK parameters, such as AUC and Cmax, could not be
derived from modeling of the sparse sampling data (3) and could be as-
sessed only in the subset of patients with intensive PK profiles collected at
week 4. The PK parameters used for this analysis for the entire treatment
population were calculated for the interval from week 0 to week 48 using
the observed sparsely collected PK samples only. These PK parameters
include the following.
GM Ctrough (C12 for BID dosing; C24 for QD dosing). The geometric
mean (GM) was defined as the geometric mean of all samples for a par-
ticular patient collected between 11 and 13 h postdose (for GM C12) or
between 22 and 26 h postdose (for GM C24). This parameter was exam-
ined because response to antiretroviral therapies is often thought to be
driven by trough drug concentrations in plasma (Ctrough). At weeks 4, 8,
24, and 48, PK samples were drawn prior to the morning dose, which
aimed to provide an adequate number of samples to capture the trough
plasma concentration for both QD and BID dosing and allow for calcula-
tion of a geometric mean. Additional samples collected without respect to
time may also add to the number of samples falling between the defined
time windows postdose.
Call. The geometric mean of all observed concentrations (Call) was
defined as the geometric mean of all samples for a particular patient,
regardless of when they were collected.
Cmin. The minimum of all observed concentrations (Cmin) was de-
fined as the minimum value of all samples for a particular patient, regard-
less of the time of collection. Based on analyses of the intensive sampling
data from phase I and II studies, a high prevalence of secondary peaks was
observed, indicating that samples within the defined window for trough
concentrations may miss the true minimum concentration. This measure
will assess the impact of particularly low observed concentrations in
plasma.
Summary statistics (geometric mean with percent coefficient of vari-
ation [%CV]) were calculated for both the sparse PK parameters (GM C12
or GM C24, Call, and Cmin) and the intensive PK parameters (AUC0 –12 or
AUC0 –24, C12 or C24, Cmax, and Tmax) for each treatment arm of the study
(BID or QD). AUC parameters (AUC0 –12 for BID and AUC0 –24 for QD)
were analyzed using a one-way analysis-of-variance (ANOVA) model
containing a single factor of treatment (BID or QD). PK parameters were
transformed in the natural log scale before analysis and back transformed
for reporting. The geometric mean ratio (GMR) estimate (2  AUC0 –12
for BID versus AUC0 –24 for QD) and 90% confidence interval (CI) were
also calculated. Similar analyses were performed for Cmax and Ctrough.
PK/PD analyses. The analyses described below were conducted on 3 data
sets: (i) BID arm alone, (ii) QD arm alone, and (iii) BID and QD arms pooled.
Logistic regression models were used to explore the PK/PD associations be-
tween the various PK parameters and the proportion of patients with HIV
RNA levels of 50 copies/ml at week 48, HIV RNA levels of 400 copies/ml
at week 48, and the occurrence of virologic failure. In this study, virologic
failure was defined as having an HIV RNA level of 50 copies/ml at week 24
of the study and virologic relapse was defined as an HIV RNA level of 50
copies/ml on two consecutive measurements at least 1 week apart after an
initial response defined by an HIV RNA level of 50 copies/ml. All PK/PD
analyses used the observed failure (OF) approach for the various PD end-
points; the OF approach counts as failures only those patients who discon-
tinue due to lack of efficacy, and it therefore considers only the virologic effect
of treatment. In addition to using the PK parameter of interest (in log10 scale)
as the explanatory variable, the baseline HIV RNA level (log10 copies/ml) was
included in the logistic regression model. Covariates such as age and gender
were not included in the model, since they have been found to be noninflu-
ential in previous analyses of raltegravir PK (3) and not significant prognostic
factors in previous phase II and III efficacy analyses (17, 20). The estimated
odds ratio with 95% CI and the associated P value for the association between
each sparse PK parameter and each PD parameter were calculated. The odds
ratio coefficient resulting from the regression model can be interpreted as the
fold change in the odds (probability of the event occurring over the probabil-
ity of the event not occurring) of the response for each 1-unit increase on the
log10 scale in the PK parameter. A similar logistic regression model was
applied to the analysis on the occurrence of virologic failure. To graph-
ically represent the observed PK/PD relationships, the probability of
achieving the efficacy endpoint was calculated from the following
equation: log[p/(1  p)]  a  (b  log10 x1)  (c  log10 x2), where p
is the probability of achieving the efficacy endpoint (i.e., HIV RNA  50
copies/ml), x1 is the baseline HIV RNA level in copies/ml, x2 is the PK
parameter being examined (i.e., GM Ctrough), and a, b, and c are the con-
stants that are fit to the observed data in the logistic regression. Receiver
operating characteristic (ROC) curves were also constructed to assess
whether using a single threshold of the sparse PK parameter can predict
the above-mentioned PD endpoints well. Taking HIV RNA at 50 cop-
ies/ml at week 48 as an example, the prediction rule would be that a patient
will achieve (or fail to achieve) this criterion if the PK parameter is above
(or below) the threshold value. With an ROC curve, sensitivity is plotted
against 1  specificity, where sensitivity (or specificity) is defined as the
observed proportion of correctly predicted failures (or responder).
RESULTS
Pharmacokinetic analyses. As detailed previously, sparse PK
samples were collected for all patients in both arms (400 mg BID
and 800 mg QD) of the study, with a subset of patients having
intensive PK profiles collected at week 4. In the intensive PK sub-
group, daily exposures to raltegravir (AUC0 –24) were similar be-
tween the two regimens (Table 1), but patients on 800 mg QD
experienced approximately 4-fold-higher Cmax and 6-fold lower
Ctrough values than those on 400 mg BID (Table 1 and Fig. 1). GM
Ctrough values were similarly lower in the analysis of sparse PK
data, with geometric mean ratios (GMR) comparing Ctrough values
for the QD versus BID arms of 0.15 (6-fold lower) in the intensive
PK data and 0.22 (4.5-fold lower) in the sparse PK data. To exam-
ine the effect of food on the pharmacokinetics of raltegravir, indi-
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vidual concentrations in plasma as a function of the time since last
dose, stratified by meal type, were examined for both the QD and
BID arms. In the sparse PK sampling data set, there did not appear
to be an obvious trend of the influence of meal type on raltegravir
plasma concentrations (data not shown). Intensive PK profiles for
patients in QDMRK were generally consistent with previous ob-
servations of HIV-infected patients (12) and of healthy volunteers
(3), where raltegravir concentrations declined from Cmax in a bi-
exponential manner with an initial half-life of approximately 1 h
and a terminal half-life of approximately 9 h. In both the sparse
and intensive PK data sets, the GM Ctrough plasma concentrations
in both arms of the study exceeded 31 nM, the mean in vitro 95%
inhibitory concentration (IC95) of raltegravir for wild-type HIV-1
in the presence of 50% normal human serum; however, GM
Ctrough values for the 800-mg-QD arm of the study were approxi-
mately 4.5-fold and 6-fold lower than in the 400-mg-BID arm,
respectively, in the sparse and intensive data sets. Additionally, in
the 400-mg-BID arm of the intensive PK data set, Ctrough values for
all subjects exceeded 31 nM. The geometric mean of Cmin for both
arms of the study in the sparse PK data set also exceeded 31 nM;
however, a greater proportion of individuals on 800 mg QD
(42.4%) exhibited Cmin below 31 nM than individuals on 400 mg
BID (13.8%). Nanomolar values can be converted to ng/ml by
multiplying by 0.4444 (the molecular weight of raltegravir is 444.4
g/mol). For instance, the above-mentioned IC95 of 31 nM is equal
to 13.8 ng/ml.
PK/PD analyses. To explore the potential association between
sparse PK parameter values and antiretroviral responses for pa-
tients receiving raltegravir at 800 mg QD or 400 mg BID, logistic
regression models were used to analyze each of 3 data sets: (i) the
BID arm alone, (ii) the QD arm alone, and (iii) the BID and QD
arms pooled for the association between each sparse PK parameter
and each of the response parameters (HIV RNA level of 400
copies/ml at week 48, HIV RNA level of 50 copies/ml at week 48,
and virologic failure by week 48). The estimated odds ratios are
presented in Table 2. For patients in the BID arm, there was no
indication of any significant PK/PD association over the range of
tested PK values, which is consistent with prior analyses of PK/PD
data after BID administration in the treatment-naive population.
In the analysis of the QD arm, only 1 significant relationship was
identified (between Call and HIV RNA levels of 400 copies/ml);
however, consistent trends in the expected direction are observed
for each of the PK parameters and virologic endpoints. When data
from both arms of the study are pooled, many significant relation-
ships emerge, again trending in the expected direction. The in-
creased degree of significance in the observed PK/PD relationships
when both arms are included in the analysis is likely due to a
combination of both a higher number of individuals included in
the pooled analysis and a wider range of observed PK parameters
spanning both the QD and BID arms.
All of the sparse PK parameters examined in this study (GM
Ctrough, Call, and Cmin) appear to be associated with efficacy, and as
illustrated by the logistic regression results shown in Table 2 and
the ROC analysis discussed below, all three parameters appear to
FIG 1 Arithmetic mean (SE) concentration-time profiles for the subset of
patients with intensive PK sampling at week 4. For the intensive PK evaluation,
samples were collected at the following time points: predose and 0.5, 1, 1.5, 2,
3, 4, 6, 8, 12, and 24 h postdose.





Raltegravir QD group Raltegravir BID group
No. of
patients GM (% CV‡)
No. of
patients GM (% CV‡)
Intensive pharmacokinetic profiles
AUCa (M · h) 22 30.87 (70) 20 13.14 (99) 1.17 (0.80, 1.72)
Cmax (M) 22 13.46 (69) 20 3.38 (135) 3.98 (2.58, 6.16)
Ctrough
b (nM) 22 40 (111) 20 257 (167) 0.15 (0.09, 0.26)
Sparse pharmacokinetic samples
Call (nM) 380 196 (176) 384 455 (92) 0.43 (0.38, 0.49)
GM Ctrough
c (nM) 245 83 (140) 304 380 (126) 0.22 (0.19, 0.25)
Cmin (nM) 380 46 (189) 384 106 (143) 0.43 (0.38, 0.50)
a AUC0-12 was determined for the BID arm, and AUC0-24 was determined for the QD arm. The ratio is for 24-h exposure: AUC0-24 QD/(2  AUC0-12 BID).
b Ctrough  C12 for BID and C24 for QD.
c GM Ctrough was calculated from sparse PK samples using all concentration measurements between 11 and 13 h postdose for a BID recipient or between 22 and 26 h postdose for a
QD recipient.
d GM values were back transformed from log scale. % CV  100  es2  1, where s2 is the observed variance on the natural log scale.
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be similar in terms of predictive value. Since GM Ctrough is the
parameter most similar to a traditional PK parameter and the one
that would be easiest to measure in a clinical context, further anal-
yses and discussion focus on this parameter.
The graphical description of the PK/PD relationship between GM
Ctrough and the probability of achieving an HIV RNA level of 50
copies/ml stratified by log10 baseline HIV RNA for the QD treatment
arm shows the expected trend, that a higher GM Ctrough value in-
creases the probability of achieving an HIV RNA level of 50 cop-
ies/ml (Fig. 2). This relationship is also evident when examining the
data arranged by quartiles of the GM Ctrough data and the percentage
of patients in each quartile that achieved an HIV RNA level of 50
copies/ml, where there is an observed drop-off in efficacy for patients
in the 800-mg-QD arm of the study in the lowest quartile of GM
Ctrough (Fig. 2).
As an alternative method of examining the multivariate influ-
ence of both PK and the baseline viral load on the antiviral re-
sponse, GM Ctrough is plotted against the log10 of baseline HIV
RNA, with different symbols representing the QD and BID arms
of the study, and if the patient did or did not achieve HIV RNA
levels of 50 copies/ml (Fig. 3). Results of this analysis indicate
that in both treatment arms, failure to achieve an HIV RNA level
of 50 copies/ml appears predominantly at high baseline HIV
RNA levels, with 40 of the 51 treatment failures clustered in the
top two quartiles of baseline HIV RNA (Q3 and Q4 in Fig. 3). This
trend between virologic response and baseline HIV RNA has also
been seen in prior analyses of raltegravir in both treatment-naive
(17) and treatment-experienced (20) patients. Additionally, in the
800-mg-QD arm, those who failed to achieve HIV RNA levels of
50 copies/ml appear clustered at lower values of GM Ctrough,
while those in the 400-mg-BID arm do not show an obvious trend
in regard to GM Ctrough, consistent with previous analyses (22).
This is also evident by examination of the difference in GM Ctrough
levels in the highest quartiles of baseline HIV RNA, where GM
Ctrough levels for treatment failures are approximately 130 nM, and
GM Ctrough levels for treatment successes are approximately
200 nM.
An ROC analysis was conducted, looking at the QD arm of the
study with an efficacy endpoint of HIV RNA at 50 copies/ml
(Fig. 4). Results of this analysis indicate that none of the three
sparse PK parameters examined give a value that yields a very
sensitive or specific threshold for efficacy. Additionally, log10





Value for response groupb
HIV RNA  50 at wk 48 HIV RNA  400 at wk 48 Virologic failure
No. of
patientsc Odds ratio P value
No. of
patientsc Odds ratio P value
No. of
patientsc Odds ratio P value
RAL, 400 mg BID
GM C12 300 278 0.7 (0.2, 1.8) 0.412 293 1.3 (0.2, 7.5) 0.773 21 1.5 (0.5, 4.1) 0.471
Call 373 343 1.2 (0.4, 3.9) 0.729 361 0.8 (0.1, 4.6) 0.792 31 1.3 (0.4, 4.0) 0.694
Cmin 373 343 1.2 (0.5, 2.8) 0.698 361 0.6 (0.2, 2.6) 0.537 31 0.8 (0.4, 2.0) 0.697
RAL, 800 mg QD
GM C24 237 208 2.0 (0.8, 5.5) 0.154 220 3.2 (0.8, 12.3) 0.086 34 0.5 (0.2, 1.1) 0.091
Call 365 318 1.7 (0.9, 3.3) 0.095 338 2.5 (1.1, 5.8) 0.034 53 0.6 (0.3, 1.2) 0.139
Cmin 365 318 1.7 (0.9, 3.2) 0.085 338 1.5 (0.7, 3.2) 0.321 53 0.6 (0.3, 1.1) 0.090
Pooled data
GM Ctrough 537 486 1.6 (0.9, 2.8) 0.085 513 3.5 (1.5, 8.1) 0.003 55 0.5 (0.3, 0.9) 0.012
Call 738 661 1.9 (1.2, 3.3) 0.012 699 2.8 (1.4, 5.6) 0.004 84 0.6 (0.3, 0.9) 0.023
Cmin 738 661 1.8 (1.1, 2.8) 0.021 699 1.6 (0.8, 3.0) 0.158 84 0.6 (0.3, 0.9) 0.011
a Number of patients with both pharmacokinetic and efficacy data.
b Odds ratio represents the fold change in the odds (probability of the event occurring over probability of the event not occurring) of the response for each 1-unit increase on the
log10 scale in the PK parameter. HIV RNA levels are expressed as copies/ml.
c Number of patients with event.
FIG 2 Probability of achieving HIV RNA levels of 50 copies/ml as a function
of the GM Ctrough and stratified by log baseline HIV RNA for the 800-mg-QD
treatment arm, showing the PK/PD relationship for the mean baseline viral
load (solid) and the 25% and 75% quartiles (dashed). Probability curves are
superimposed above observed data (divided by quartiles) for the GM Ctrough
and the percentage of patients observed with HIV RNA levels of 50 copies/
ml. The median GM Ctrough value, range of GM Ctrough values in the quartile,
number of subjects achieving HIV RNA levels of 50 copies/ml, and total
number of subjects in each quartile are displayed below each quartile.
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baseline HIV RNA provides the best separation between true-
positive (sensitivity) and false-positive (1  specificity) results,
yielding better separation than any of the PK parameters exam-
ined. Specifically, the ROC analysis resulted in a threshold value of
4.90 for the log10 baseline HIV RNA, corresponding to a baseline
HIV RNA level of approximately 80,000 copies/ml. These results
indicate that there is not a specific value of any of the PK param-
eters examined that provides a threshold for virologic response.
Other possible drivers of efficacy, such as the time above a thresh-
old concentration, could not be evaluated from this data set due to
the sparse PK sampling scheme employed for the majority of pa-
tients in the study and the small number of virologic failures
within the intense PK subgroup. Specifically, 3 patients in the QD
arm and 1 patient in the BID arm of the intense PK subgroup
experienced virologic failure.
DISCUSSION
In this study of raltegravir given once daily versus twice daily,
failure to achieve an HIV RNA level of 50 copies/ml appeared
predominantly at high baseline HIV RNA levels in both treatment
arms and was also associated with lower values of GM Ctrough in
the 800-mg-QD arm. The patients with the greatest risk of failure
were those with a combination of high baseline HIV RNA and low
GM Ctrough (Fig. 3). These findings are consistent with results of
the ROC analysis, which also identified the baseline viral load as
the parameter best associated with providing a threshold for the
greatest degree of both sensitivity and specificity in efficacy. Al-
though none of the raltegravir PK parameters examined yielded
sensitive or specific threshold values, they were also significantly
associated with efficacy in a logistic regression analysis that ac-
counted for the effect of baseline HIV RNA. With the current data
set, correlations are seen between efficacy and several summary
measures of raltegravir PK, including trough concentrations, but
we cannot evaluate other possible drivers of efficacy, such as the
time above a threshold concentration, due to the sparse PK sam-
pling scheme employed for the majority of patients in the study
and the small number of virologic failures within the intense PK
subgroup. The observation of only a slight drop-off in efficacy
with QD treatment (83% versus 89%) (6) corresponding with a
severalfold drop in Ctrough suggests that BID administration of
raltegravir results in Ctrough values well along the exposure-re-
sponse plateau and that the pharmacokinetics of this regimen are
above the minimum required for efficacy. However, the QD arm
of the study was inferior to the BID arm in the context of similar
daily exposures, implying that the shape of the PK curve is impor-
tant for the long-term efficacy of raltegravir and that the mainte-
nance of raltegravir levels throughout the dosing interval is im-
portant for efficacy.
Results from the intensive pharmacokinetic analysis in a sub-
group of patients in each treatment arm of the QDMRK study
indicated that total daily exposures were similar between once-
daily and twice-daily regimens; however, administration of ralte-
gravir at a once-daily dose of 800 mg resulted in a different shape
to the PK profile than the administration of 400 mg twice daily.
Specifically, QD dosing resulted in a higher peak-to-trough ratio,
with 4-fold-higher Cmax and 6-fold lower Ctrough values relative to
those for 400 mg BID. Analysis of sparsely sampled PK data from
all patients in the study confirmed this observation, since GM
Ctrough values were similarly lower (4.5-fold) when comparing
data from the QD arm relative to those from the BID arm.
PK/PD analyses of patients in the BID arm of the study revealed
FIG 4 ROC curve for the 800-mg-QD arm. The ROC analysis aims to identify
a threshold value of the various parameters which give the best balance be-
tween true positive and true negative. The inset table displays the parameter
value, sensitivity, and specificity for the value that yields the largest separation
between true positive and true negative. Log10 baseline HIV RNA provides the
best separation between true-positive (sensitivity) and false-positive (1 
specificity) results, with no PK parameter providing a very sensitive or specific
threshold.
FIG 3 GM Ctrough and log10 baseline HIV RNA as a predictor for achieving
HIV RNA levels of 50 copies/ml for pooled data from 800-mg-QD and
400-mg-BID arms. Patients of BID arm failing to achieve HIV RNA levels
of 50 copies/ml (open black circles), BID arm achieving HIV RNA levels
of 50 copies/ml (open red triangles), QD arm failing to achieve HIV RNA
levels of 50 copies/ml (blue plus signs), and QD arm achieving HIV RNA
levels of 50 copies/ml (green asterisks) are indicated. Values along the
right side of the plot represent the GM Ctrough values in each quartile of
baseline viral load for patients who achieved (or failed to achieve) HIV
RNA levels of 50 copies/ml. Values in parentheses represent the numbers
of patients in each quartile of baseline viral load who achieved (or failed to
achieve) HIV RNA levels of 50 copies/ml.
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no indication of significant PK/PD associations over the range of
tested PK parameter values. In contrast, analysis of data from the
QD arm revealed an apparent association between PK and viro-
logic outcome measures; however, no clear threshold value for any
of the PK parameters could be identified (Fig. 4). Whether the
most important parameter is Cmin, GM Ctrough, or Call cannot be
determined using the data from this study; further analyses and
discussion focus on GM Ctrough, since this is the parameter most
likely to be of use clinically. Examination of the QD arm data
grouped by quartiles showed a drop-off in the lowest quartile of
Ctrough with respect to efficacy. Patients in this lowest quartile had
a mean Ctrough value of 28.2 nM, with a range from 7.1 to 43.3 nM.
Note that this mean Ctrough value is just below 31 nM, the mean in
vitro IC95 of raltegravir for wild-type HIV-1 in the presence of 50%
normal human serum. Similar trends were not observed for the
BID arm when the quartiles of Ctrough data were examined, con-
sistent with the observation that the values of raltegravir PK pa-
rameters in the highest QD arm quartile are similar to those in the
lowest BID arm quartile. Specifically, in the QD arm, the mean
Ctrough values in the two highest quartiles were 100 and 245 nM,
while in the BID arm mean Ctrough values in the two lowest quar-
tiles were 135 and 293 nM. These results are consistent with find-
ings for the investigational integrase inhibitors elvitegravir (5) and
dolutegravir (18), where it has been reported that efficacy is cor-
related with Ctrough.
The lack of a significant PK/PD association coupled with the
high response rate of 89% observed for the BID arm indicates that
key PK parameter values are likely above the minimum required
for efficacy. As observed in previous studies (2, 9, 12, 15, 22), the
high degree of variability in the observed raltegravir pharmacoki-
netics, both interoccasional and interindividual, precludes the use
of therapeutic drug monitoring for twice-daily dosing of the cur-
rently marketed formulation.
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